Structured evidence table for Beta Glucan Skin Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Beta Glucan Skin Health Randomized Trial | Despite major advances in insulin analogs, pumps, and continuous glucose monitoring, many individuals with T1D continue to experience substantial glycemic variability and hypoglycemia risk, supporting the need for adjunctive, physiology-based strategies beyond insulin replacement alone. | 3 | Grammatiki Maria (2026) | Nutritional Interventions in Type 1 Diabetes: Boosting Residual GLP-1 Responses—Is It an Option? |
| Beta Glucan Skin Health Randomized Trial | Beyond its acute insulinotropic and glucagonostatic actions, GLP-1 has been associated with beta-cell protective effects in preclinical models, including improved beta-cell survival and proliferative signaling, which has fueled interest in incretin-targeted approaches as disease modifiers rather than glucose-lowering tools alone []. | 3 | Grammatiki Maria (2026) | Nutritional Interventions in Type 1 Diabetes: Boosting Residual GLP-1 Responses—Is It an Option? |
| Beta Glucan Skin Health Randomized Trial | Postprandial GLP-1 levels in T1D are comparable to or slightly reduced compared to healthy controls, with exaggerated glucagon responses persisting despite GLP-1 elevation [,,]. | 3 | Grammatiki Maria (2026) | Nutritional Interventions in Type 1 Diabetes: Boosting Residual GLP-1 Responses—Is It an Option? |
| Beta Glucan Skin Health Randomized Trial | Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive pancreatic beta-cell destruction, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin therapy. | 3 | Grammatiki Maria (2026) | Nutritional Interventions in Type 1 Diabetes: Boosting Residual GLP-1 Responses—Is It an Option? |
| Beta Glucan Skin Health Randomized Trial | However, supplementation with oat grain extract capsules was associated with significantly higher improvements in the outcomes in the treatment group compared with the control group. | 4 | Nasrpour Tahouneh F (2026) | Evaluating the effects of standardized hydroalcoholic extract of oat grains (<i>Avena sativa</i> L.) capsules as an adjunctive treatment on allergic rhinitis. |
| Beta Glucan Skin Health Randomized Trial | Conclusion The dried extract of oat grains ( Avena sativa L.) capsules was an effective adjunctive therapy to improve allergic rhinitis symptoms. | 4 | Nasrpour Tahouneh F (2026) | Evaluating the effects of standardized hydroalcoholic extract of oat grains (<i>Avena sativa</i> L.) capsules as an adjunctive treatment on allergic rhinitis. |
| Beta Glucan Skin Health Randomized Trial | Objective Allergic rhinitis is a chronic inflammatory disease which exists throughout people's lives. | 4 | Nasrpour Tahouneh F (2026) | Evaluating the effects of standardized hydroalcoholic extract of oat grains (<i>Avena sativa</i> L.) capsules as an adjunctive treatment on allergic rhinitis. |
| Beta Glucan Skin Health Randomized Trial | (oat) belongs to the Poaceae family and has antihistamine, anti-inflammatory, and antioxidant effects. | 4 | Nasrpour Tahouneh F (2026) | Evaluating the effects of standardized hydroalcoholic extract of oat grains (<i>Avena sativa</i> L.) capsules as an adjunctive treatment on allergic rhinitis. |
Source documents